For the Quarterly Period Ended March 31, 2024 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Florida 26-2792552 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1775 West Oak Commons Ct NE Marietta, GA 30062 (Address of principal executive offices) (Zip Code) (770) 651-9100 (Registrant's telephone number, including area code) ☐ TRA ...

MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xenograft products to its portfolio of Advanced Wound Care and Surgical solutions. Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, "We are excited to announ ...

MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously a ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2023 Results Conference Call February 28, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright Anthony Petrone - Mizuho John Vandermosten - Zacks Operator Greetings, and welcome to the MiMedx Group Inc. Fourth Quarter and Full Ye ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Exhibit 99.1 MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $21 million, or 24% of Net Sales Management to Host Conference Call Today, February 28, 2024, at 4:30 PM ET MARIETTA, Ga., February 28, 2024 — MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Comp ...

MARIETTA, Ga., Jan. 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it has enhanced its capital structure by refinancing its existing indebtedness and obtaining additional borrowing capacity in support of the Company's future growth objectives. These new senior secured credit facilities (the "Facilities"), totaling $95 million and due in January 2029, are comprised of a $75 million revolving credit facility and a $20 million term loan facility a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-2 ...

• Go deeper and wider in Surgical Recovery Demonstrate corporate discipline around expenses 10 Management Team with Track Record of Success in MedTech Eric Smith SVP, Marketing & International BioTelemetry 12 Large and growing market opportunities Appendix Note: Some figures may not add to subtotals due to immaterial rounding differences. | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------|---------|--------|-------|-------|-------|-------| | ($ millions) | 1Q22 | 2Q22 | ...

Financial Data and Key Metrics Changes - Q2 2023 net sales grew by approximately 21.5% year-over-year to $81.3 million, marking the highest quarterly net sales performance in nearly four years [13][36] - Gross profit margin improved to 83.3%, up from 82.3% year-over-year, reflecting a 100 basis point increase [37] - Adjusted EBITDA was $14.1 million, a significant improvement from an adjusted EBITDA loss of almost $1 million a year ago, representing a $15 million improvement [13][42] - The company ended the quarter with $68.7 million in cash, an increase of $7.5 million from the end of Q1 [13][45] Business Line Data and Key Metrics Changes - Wound & Surgical segment net sales totaled $80.5 million, reflecting a growth of 21.7% compared to $66.1 million last year [42] - Contribution margin for the Wound & Surgical segment was $27.6 million, representing 34.3% of Wound & Surgical net sales, compared to 21.5% in the prior year [42] - Sales in the private office sector grew by 25% year-over-year, continuing a positive trend from Q1 [17] Market Data and Key Metrics Changes - The company noted that procedure volumes are continuing to rise, contributing to market growth alongside their market share gains [55][56] - The CMS proposed physician fee schedule for 2024 indicates no major modifications to skin substitute reimbursements, which is expected to be a net positive for the company [18] Company Strategy and Development Direction - The company is focusing on enhancing its Wound & Surgical businesses due to substantial market opportunities and competitive offerings [11] - Plans include expanding the product portfolio and geographic reach, with a specific focus on adjacent markets to create additional growth drivers [20][27] - The company announced the suspension of its Knee Osteoarthritis development project to concentrate on Wound & Surgical markets [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong momentum and the expectation of continued growth, anticipating a multi-year growth phase [12][49] - The adjusted EBITDA margin is expected to exceed 20% in the second half of the year, demonstrating excellent leverage as the business scales [48] - Management highlighted the positive ruling from the 11th Circuit Court of Appeals regarding a securities class action lawsuit, which is expected to alleviate one of the largest potential claims against the company [33] Other Important Information - The company achieved its efficiency goals ahead of schedule, with Wound & Surgical contribution margin above 30% and corporate G&A below 20% of sales [30][44] - The company is optimistic about the early market development phase in Japan, expecting adoption to ramp in the coming months [19][66] Q&A Session Summary Question: What is the underlying growth profile for Wound Care and how much is from market share gains? - Management indicated that the growth is primarily driven by volume rather than price increases, with both market growth and share gains contributing to performance [55][56] Question: What are the expectations for in-office sales growth into 2024? - Management believes the fundamentals are strengthening, indicating the potential for continued double-digit growth [64] Question: What is the outlook for investigation-related expenses and R&D normalization? - Management expects investigation costs to taper off and R&D expenses to drop into the low to mid-single digits in the second half of the year [77][79] Question: Can Japan serve as a stepping stone for other parts of Asia? - While it is early, management sees potential for Japan to lead in the region, but the primary focus remains on establishing a strong market presence there [88] Question: What is the status of the Series B preferred shares? - Management noted that conversion of Series B preferred shares could occur if the share price remains above $7.7 for a specified period, potentially adding approximately 31 million shares to the diluted share count [89]